3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Ovarian Neoplasms
21
Breast Neoplasms
11
Prostatic Neoplasms
10
Fallopian Tube Neoplasms
8
Neoplasms
7
Neoplasm Metastasis
7
Pancreatic Neoplasms
6
Endometrial Neoplasms
5
Triple Negative Breast Neoplasms
4
Lung Neoplasms
3
Head and Neck Neoplasms
3
Glioblastoma
3
Carcinoma, Ovarian Epithelial
3
Small Cell Lung Carcinoma
2
Prostatic Neoplasms, Castration-Resistant
2
Glioma
2
Carcinoma, Non-Small-Cell Lung
2
Brain Neoplasms
2
Biliary Tract Neoplasms
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urologic Neoplasms
1
Urinary Bladder Neoplasms
1
Unilateral Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma
1
SCLC,Extensive Stage
1
Recurrence
1
Rectal Neoplasms
1
Prostate Adenocarcinoma
1
Interventions
Letrozole
2
trametinib
1
ribociclib
1
niraparib
1
liposomal doxorubicin
1
Topotecan
1
Taxes
1
Tamoxifen
1
Specimen Handling
1
Paclitaxel
1
Nivolumab
1
Magnetic Resonance Spectroscopy
1
Ipilimumab
1
Doxorubicin
1
CTLA-4 Antigen
1
Axitinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Cystadenocarcinoma, Serous
×
niraparib
×
1 year
×
Clear all
NCT04159155
2025-08-12
CAN-STAMP
University Health Network, Toronto
Phase 2/3
Terminated
11 enrolled